BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 10667592)

  • 21. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
    Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
    Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
    Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
    Jernström H; Borg K; Olsson H
    Mol Genet Metab; 2005; 86(1-2):320-7. PubMed ID: 16084122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
    Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
    Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
    Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients.
    Tong D; Volm T; Eberhardt E; Krainer M; Leodolter S; Kreienberg R; Zeillinger R
    Oncol Rep; 2003; 10(5):1551-3. PubMed ID: 12883740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
    Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
    Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation.
    Kowalska E; Narod SA; Huzarski T; Zajaczek S; Huzarska J; Gorski B; Lubinski J
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1302-6. PubMed ID: 15894690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method].
    Byrski T
    Ann Acad Med Stetin; 2003; 49():27-43. PubMed ID: 15552838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.
    Bau DT; Fu YP; Chen ST; Cheng TC; Yu JC; Wu PE; Shen CY
    Cancer Res; 2004 Jul; 64(14):5013-9. PubMed ID: 15256476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer.
    Blasiak J; Arabski M; Krupa R; Wozniak K; Rykala J; Kolacinska A; Morawiec Z; Drzewoski J; Zadrozny M
    Mutat Res; 2004 Oct; 554(1-2):139-48. PubMed ID: 15450412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
    Evans DG; Young K; Bulman M; Shenton A; Wallace A; Lalloo F
    Clin Genet; 2008 Apr; 73(4):338-45. PubMed ID: 18312450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selenium supplementation reduced oxidative DNA damage in adnexectomized BRCA1 mutations carriers.
    Dziaman T; Huzarski T; Gackowski D; Rozalski R; Siomek A; Szpila A; Guz J; Lubinski J; Wasowicz W; Roszkowski K; Olinski R
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2923-8. PubMed ID: 19843683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Initial Dutch results with a presymptomatic DNA tests in familial breast/ovarian carcinoma. Rotterdamse Werkgroep voor Erfelijke Tumoren].
    Klijn JG; Devilee P; van Geel AN; Tilanus-Linthorst MM; Dudok-de Wit C; Meijers-Heijboer EJ
    Ned Tijdschr Geneeskd; 1995 Mar; 139(9):439-45. PubMed ID: 7891765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.